,28 Indeed, the objective response rate (ORR) for pembrolizumab (anti-PD-1 antibody) monotherapy in advanced urothelial cancer, including bladder cancer, was reported to be 21.1% in a phase III clinical trial.29 Here, PDCD1 is linked to urinary bladder carcinoma.